.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 8,623,418

« Back to Dashboard

Claims for Patent: 8,623,418

Title:Pharmaceutical composition
Abstract: Provided herein is a pharmaceutical composition comprising an antagonist, an agonist, a seal coat, and a sequestering polymer, wherein the antagonist, agonist, seal coat and at least one sequestering polymer are all components of a single unit, and wherein the seal coat forms a layer physically separating the antagonist from the agonist from one another. Methods for manufacturing such a pharmaceutical composition are also provided. Methods for treating pain using such compositions is also demonstrated.
Inventor(s): Liang; Alfred (Edison, NJ), Matthews; Frank (Edison, NJ), Boehm; Garth (Westfield, NJ), Tang; Lijuan (Flemington, NJ), Johnson; Frank (Bridgewater, NJ), Stauffer; Joseph (Skillman, NJ)
Assignee: Alpharma Pharmaceuticals LLC (Bridgewater, NJ)
Application Number:12/336,267
Patent Claims: 1. A method of treating moderate to severe chronic pain in a patient in need thereof comprising orally administering to the patient an intact multi-layer pharmaceutical composition comprising: a core; an opioid antagonist layer, coating the core; a sequestering polymer layer which contains a charge-neutralizing additive and a hydrophobicity-enhancing additive and which coats said opioid antagonist layer; an opioid agonist layer coating the sequestering polymer layer, and; an osmotic pressure regulating agent located immediately beneath the agonist layer; wherein administration of the intact form of the composition to the patient once or twice daily for a time period of at least two weeks results in zero release of the antagonist over the time period as determined by the antagonist concentration in the plasma of the patient.

2. The method of claim 1 wherein administration of the intact form of the composition to the patient for at least a time period selected from the group consisting of four, eight, 12, 16, 20, 24, 28, 32, 36, 40 and 100 weeks.

3. The method of either claim 1 or 2 wherein the antagonist is naltrexone.

4. The method of claim 3 wherein release of naltrexone is determined by measuring plasma levels of B-naltrexol.

5. A method of treating moderate to severe chronic pain in a patients in need thereof comprising orally administering to the patients an intact multi-layer pharmaceutical composition comprising: a core; an opioid antagonist layer, coating the core; a sequestering polymer layer which contains a charge-neutralizing additive and a hydrophobicity-enhancing additive and which coats said opioid antagonist layer; an opioid agonist layer coating the sequestering polymer layer, and; an osmotic pressure regulating agent located immediately beneath the agonist layer; wherein administration of the intact form of the composition to the patients once daily for a time period of at least two weeks results in zero release of the antagonist in about 90% of the patients as determined by measuring antagonist concentration in the plasma of the patients.

6. The method of claim 5 wherein administration of the intact form of the composition to the patient for at least a time period of 28 weeks.

7. The method of either claim 5 or 6 wherein the antagonist is naltrexone.

8. The method of claim 7 wherein release of naltrexone is determined by measuring plasma levels of B-naltrexol.

9. The method of claim 2 or 3 wherein the opioid agonist is morphine.

10. The method of claim 7 or 8 wherein the opioid agonist is morphine.

11. The method of claim 9 or 10 wherein the osmotic pressure regulating agent is hydroxypropyl methylcellulose or chloride ions.

12. The method of claim 1 wherein the opioid agonist is morphine and the opioid antagonist is naltrexone.

13. A method of treating moderate to severe chronic pain in a patients in need thereof comprising orally administering to the patients an intact multi-layer pharmaceutical composition comprising: a core; an opioid antagonist layer coating the core; a sequestering polymer layer which contains a charge-neutralizing additive and a hydrophobicity-enhancing additive and which coats said opioid antagonist layer; an opioid agonist layer coating the sequestering polymer layer, and an osmotic pressure regulating agent located immediately beneath the agonist layer; wherein administration of the intact form of the composition to the patients once daily for a time period of at least two weeks results in zero release of the antagonist in about 80% of the patients as determined by measuring antagonist concentration in the plasma of the patients.

14. The method of claim 13 wherein the osmotic pressure agent is sodium chloride.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc